Completed PHASE1 INTERVENTIONAL NCT00829777

Safety Study of Intravenous 6β-Naltrexol (AIKO-150) in Opioid-Dependent Subjects (AIKO-150)

A Phase-I, Two-Stage, Double-Blind, Placebo-Controlled, Pharmacokinetic and Pharmacodynamic Trial of Low Doses of Intravenous 6β-Naltrexol (AIKO-150) in Opioid-Dependent Subjects.

Sponsor: California Pacific Medical Center Research Institute

Conditions Opiate Addiction

Interventions 6β-Naltrexol escalating doses from 0.05-0.5 mg IV

Updated 6 times since 2017 Last updated: Sep 14, 2009 Started: Mar 31, 2009 Primary completion: Sep 30, 2009 Completion: Sep 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Opiate Addiction, this trial is completed. The trial is conducted by California Pacific Medical Center Research Institute and has accumulated 6 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Mar 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

California Pacific Medical Center Research Institute

Data source: California Pacific Medical Center Research Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• San Francisco, United States